Affordable Access

Publisher Website

LIGNOCAINE METABOLITE FORMATION AS A MEASURE OF PRE-TRANSPLANT LIVER FUNCTION

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
333
Issue
8639
Identifiers
DOI: 10.1016/s0140-6736(89)92144-2
Disciplines
  • Medicine

Abstract

Abstract A method for rapid assessment of hepatic function in liver donors based on the formation of the lignocaine metabolite monoethylglycinexylidide (MEGX), was used in a prospective study of 69 donor-recipient pairs. The probability of graft survival over 120 days was significantly higher for livers from donors with MEGX test values above 90 μg/l than for those from donors with MEGX values of 90 μg/l or below. Other liver function tests (bilirubin, prothrombin time, activity of aminotransferases, glutamate dehydrogenase, and cholinesterase, indocyanine green clearance, and galactose elimination capacity) were inefficient at predicting early outcome of transplantation. For a 20-day graft survival, the MEGX test showed prognostic sensitivity of 73% and specificity of 78%. These findings suggest that the MEGX formation test could be valuable for selection of donor organs.

There are no comments yet on this publication. Be the first to share your thoughts.